GENFIT continues the development of nangibotide in ACLF with promising results

GENFIT recently presented the results of clinical trials of nangibotide, a drug for the treatment of ACLF, at the AASLD The Liver Meeting® congress. This drug, whose Phase 2 development will continue until 2027, is being studied for its ability to modulate excessive inflammation without directly affecting the immune response.

Studies have confirmed a favorable safety profile and signals of efficacy, particularly in cases of septic shock and severe COVID-19. A Phase 2a study called UPWARD is planned to further evaluate safety and efficacy in patients with grade 2 ACLF, with results expected in 2027.